HK stock market changes | Innovent Bio (01801) rose more than 4%, and the small nucleic acid drug developed jointly by ShengYin Bio and Innovent Bio has been approved for clinical use.

According to the app of Zhītōng Cáijīng, Innovent Bio (01801) rose more than 4%. As of publication, it has risen 4.43% to HK$37.70, with a turnover of HK$749.836 million. In terms of news, on July 9th, Aurora Mobile-backed Suzhou Santen Pharmaceutical Co., Ltd. announced that the clinical trial application for SGB-3908 injection, a small nucleic acid (siRNA) drug developed jointly with Innovent Biopharmaceuticals for the treatment of hypertension, has obtained the implied permission for clinical trial application from the drug evaluation center (CDE) of the National Medical Products Administration (acceptance number: CXHL2400426), for the treatment of high blood pressure.

Zhitong FinanceJul 10 22:11 ET

Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.

Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.

Zhitong FinanceJul 10 03:46 ET

GF Sec: Rapid Development of RNAi Therapy, Future Value Expected to Expand from Rare Diseases to Chronic Diseases.

siRNA drugs have unique therapeutic advantages in clinical treatment. With breakthroughs in delivery systems in recent years, the RNAi field has developed rapidly. Six siRNA drugs have been approved for marketing globally, and hundreds of pipelines are in clinical research, covering numerous treatment areas from rare diseases to common chronic diseases. They have great clinical and commercial value.

Zhitong FinanceJul 9 23:04 ET

Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).

Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.

Zhitong FinanceJul 8 20:58 ET

Soochow Securities: "Implementation Plan for Supporting the Development of Innovative Drugs Across the Entire Chain" Approved, and the innovative drugs sector is expected to strengthen.

Soochow Securities released research reports stating that the specific provisions of the "Implementation Plan for Full-chain Support of Innovative Drug Development" are expected to be implemented soon. In addition, the innovative drug sector is currently at a historically relatively low level. In the second half of the year, there will be multiple catalysts such as the ESMO conference, WCLC conference, medical insurance negotiations, and expectations for the innovative drug sector going global, which may lead to a strong performance in the innovative drug sector.

Zhitong FinanceJul 8 02:34 ET

Innovent Bio has launched a new Environmental, Social, and Governance (ESG) website to practice sustainable development and corporate responsibility.

On July 8th, 2024, San Francisco, USA, and Suzhou, China / PRNewswire / - Environmental, social and governance (ESG) are key indicators for measuring a company's long-term sustainable development capabilities. Innovent Biologics has always actively responded to the United Nations Sustainable Development Goals (SDGs) and assisted in the implementation of the Health China initiative. It regards green, healthy and sustainable development as its long-term important development strategy. Recently, the Innovent Biologics Pharmaceutical Group officially launched the ESG official website, marking the company's firm commitment to sustainability, corporate responsibility and ethical business practices, while demonstrating Innovent Bio's excellence and innovation.

PR NewswireJul 7 20:00 ET